Electrome is lining up EXACTLY like every med‑tech breakout of the last decade — but with one massive difference: the entire platform sits on top of BIEL’s FDA‑cleared PEMF technology.
Whoop had LeBron. Hyperice had Mahomes. Eight Sleep had A‑Rod. Levels had the influencer army. Every one of those companies exploded AFTER celebrity validation.
Electrome already has Orel Hershiser — not as a mascot, but as an investor + strategic advisor. That’s a stronger role than most celebrity‑backed med‑techs ever get.
And here’s the part nobody seems to grasp:
Electrome’s “credibility advantage” comes directly from BIEL’s 30 years of clinical data and FDA clearances.
Electrome didn’t invent PEMF.
Electrome didn’t get the FDA clearances.
Electrome didn’t build the clinical foundation.
BIEL did.
Electrome is the front‑end brand.
BIEL is the regulatory engine powering the entire thing.
Why This Matters for BIEL (the part the market is sleeping on)
1. Electrome’s credibility = BIEL’s credibility
Electrome is being praised for having what Whoop, Hyperice, Eight Sleep, and Levels didn’t: FDA‑cleared tech. That FDA clearance is BIEL’s.
Every time Electrome gets attention, the underlying message is:
“This tech is real, it’s regulated, and it’s safe.”
That’s BIEL’s moat.
2. Electrome’s retail rollout will expand the PEMF category — and BIEL is the cheapest FDA‑cleared PEMF device in the entire market
Electrome drives awareness.
BIEL captures spillover demand.
This is the same pattern that made:
Hyperice → explode recovery category
Whoop → explode biometrics category
Eight Sleep → explode sleep‑tech category
Electrome is about to do that for PEMF.
And BIEL is the only FDA‑cleared PEMF product at consumer price points.
3. Celebrity validation + FDA clearance is the exact combination that historically precedes med‑tech breakouts.
Electrome has:
Celebrity validation
Regulatory legitimacy
Retail rollout timing
This is the same setup that preceded:
Hyperice’s unicorn jump
Whoop’s $3.6B valuation
Eight Sleep’s $500M valuation
Except Electrome’s foundation is stronger because it’s built on FDA‑cleared PEMF. And that FDA clearance belongs to BIEL.
4. BIEL is the “Intel Inside” of Electrome’s entire platform
Electrome is the brand.
BIEL is the technology.
Electrome’s success doesn’t dilute BIEL — it amplifies it.
This is the first time in BIEL’s 20‑year history that:
A celebrity investor is validating the tech
A modern brand is commercializing it
A retail rollout is coming
A narrative is forming around FDA‑cleared PEMF
BIEL has never had this kind of tailwind.
Electrome is following the exact same playbook as Whoop, Hyperice, Eight Sleep, and Levels — but with a stronger foundation because the tech is FDA‑cleared. And that FDA‑cleared tech belongs to BIEL. Electrome’s rise is BIEL’s inflection point. The market hasn’t priced that in yet.
Whoop had LeBron. Hyperice had Mahomes. Eight Sleep had A‑Rod. Levels had the influencer army. Every one of those companies exploded AFTER celebrity validation.
Electrome already has Orel Hershiser — not as a mascot, but as an investor + strategic advisor. That’s a stronger role than most celebrity‑backed med‑techs ever get.
And here’s the part nobody seems to grasp:
Electrome’s “credibility advantage” comes directly from BIEL’s 30 years of clinical data and FDA clearances.
Electrome didn’t invent PEMF.
Electrome didn’t get the FDA clearances.
Electrome didn’t build the clinical foundation.
BIEL did.
Electrome is the front‑end brand.
BIEL is the regulatory engine powering the entire thing.
Why This Matters for BIEL (the part the market is sleeping on)
1. Electrome’s credibility = BIEL’s credibility
Electrome is being praised for having what Whoop, Hyperice, Eight Sleep, and Levels didn’t: FDA‑cleared tech. That FDA clearance is BIEL’s.
Every time Electrome gets attention, the underlying message is:
“This tech is real, it’s regulated, and it’s safe.”
That’s BIEL’s moat.
2. Electrome’s retail rollout will expand the PEMF category — and BIEL is the cheapest FDA‑cleared PEMF device in the entire market
Electrome drives awareness.
BIEL captures spillover demand.
This is the same pattern that made:
Hyperice → explode recovery category
Whoop → explode biometrics category
Eight Sleep → explode sleep‑tech category
Electrome is about to do that for PEMF.
And BIEL is the only FDA‑cleared PEMF product at consumer price points.
3. Celebrity validation + FDA clearance is the exact combination that historically precedes med‑tech breakouts.
Electrome has:
Celebrity validation
Regulatory legitimacy
Retail rollout timing
This is the same setup that preceded:
Hyperice’s unicorn jump
Whoop’s $3.6B valuation
Eight Sleep’s $500M valuation
Except Electrome’s foundation is stronger because it’s built on FDA‑cleared PEMF. And that FDA clearance belongs to BIEL.
4. BIEL is the “Intel Inside” of Electrome’s entire platform
Electrome is the brand.
BIEL is the technology.
Electrome’s success doesn’t dilute BIEL — it amplifies it.
This is the first time in BIEL’s 20‑year history that:
A celebrity investor is validating the tech
A modern brand is commercializing it
A retail rollout is coming
A narrative is forming around FDA‑cleared PEMF
BIEL has never had this kind of tailwind.
Electrome is following the exact same playbook as Whoop, Hyperice, Eight Sleep, and Levels — but with a stronger foundation because the tech is FDA‑cleared. And that FDA‑cleared tech belongs to BIEL. Electrome’s rise is BIEL’s inflection point. The market hasn’t priced that in yet.
1
